Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Masterson

Showing results (241-250 of 256) with videos related to

Pageof 26
Sort By:
Journal of Medicinal Chemistry|September 1, 2006
Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugatesGeoff Wells, Christopher R H Martin, Philip W Howard, et al.
Scientific Reports|July 12, 2018
Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirineJohn A Hartley, Michael J Flynn, John P Bingham, et al.
The American Journal of Surgical Pathology|April 21, 2026
Discontinuous Involvement of the Spermatic Cord by Germ Cell Tumors Should Not Be Considered Pathologic Stage M1: An International Multi-Institutional StudyJoão Lobo, Dheeraj Chinnam, Kvetoslava Michalova, et al.
Molecular Cancer Therapeutics|March 3, 2021
Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATRShenlan Mao, Raghothama Chaerkady, Wen Yu, et al.
The Journal of Sexual Medicine|June 25, 2026
Impact of testosterone therapy and hypogonadism on treatment outcomes in Peyronie's disease: a multicenter retrospective analysis of collagenase clostridium histolyticum therapyBeatriz S Hernandez, Arnaav Walia, Peyton Coady, et al.
Molecular Cancer Therapeutics|August 19, 2016
ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological MalignanciesMichael J Flynn, Francesca Zammarchi, Peter C Tyrer, et al.
JCO Precision Oncology|March 2, 2026
Erratum: Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell TumorsRebecca Hassoun, Reuben Ben-David, John P Sfakianos, et al.
JCO Precision Oncology|September 24, 2025
Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell TumorsRebecca Hassoun, Reuben Ben-David, John P Sfakianos, et al.
Journal of Medicinal Chemistry|November 8, 2017
Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-LinkersStephen J Gregson, Luke A Masterson, Binqing Wei, et al.
Sexual Medicine|May 6, 2026
Efficacy and safety of collagenase <i>Clostridium histolyticum</i> in men who have sex with menJake A Miller, Muhammed A Moukhtar Hammad, Lucas G C R de Amorim, et al.
Pageof 26

Showing results (241-250 of 256) with videos related to

Sort By:
Pageof 26
Journal of Medicinal Chemistry|September 1, 2006
Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugatesGeoff Wells, Christopher R H Martin, Philip W Howard, et al.
Scientific Reports|July 12, 2018
Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirineJohn A Hartley, Michael J Flynn, John P Bingham, et al.
The American Journal of Surgical Pathology|April 21, 2026
Discontinuous Involvement of the Spermatic Cord by Germ Cell Tumors Should Not Be Considered Pathologic Stage M1: An International Multi-Institutional StudyJoão Lobo, Dheeraj Chinnam, Kvetoslava Michalova, et al.
Molecular Cancer Therapeutics|March 3, 2021
Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATRShenlan Mao, Raghothama Chaerkady, Wen Yu, et al.
The Journal of Sexual Medicine|June 25, 2026
Impact of testosterone therapy and hypogonadism on treatment outcomes in Peyronie's disease: a multicenter retrospective analysis of collagenase clostridium histolyticum therapyBeatriz S Hernandez, Arnaav Walia, Peyton Coady, et al.
Molecular Cancer Therapeutics|August 19, 2016
ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological MalignanciesMichael J Flynn, Francesca Zammarchi, Peter C Tyrer, et al.
JCO Precision Oncology|March 2, 2026
Erratum: Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell TumorsRebecca Hassoun, Reuben Ben-David, John P Sfakianos, et al.
JCO Precision Oncology|September 24, 2025
Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell TumorsRebecca Hassoun, Reuben Ben-David, John P Sfakianos, et al.
Journal of Medicinal Chemistry|November 8, 2017
Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-LinkersStephen J Gregson, Luke A Masterson, Binqing Wei, et al.
Sexual Medicine|May 6, 2026
Efficacy and safety of collagenase <i>Clostridium histolyticum</i> in men who have sex with menJake A Miller, Muhammed A Moukhtar Hammad, Lucas G C R de Amorim, et al.
Pageof 26